Braveheart Bio, Inc. Common Stock BRVE
$25.02
-14.32%
at last close
Market Cap$2.25 billion
P/E Ratio—
Div Yield—
Volume1.57M
52-Week Range
$24.30$32.00
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $45.25 (+80.9% upside)
Key Stats
- Today's Range
- $24.63 – $28.90
- 50-Day Range
- $24.30 – $32.00
- 52-Week Range
- $24.30 – $32.00
- Volume
- 1.57 million shs
- Average Volume
- 455K shs
- Market Cap
- $2.25 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.94%
- Days to Cover
- 1.30
About Braveheart Bio, Inc. Common Stock
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Related Stocks
Compare head-to-head: BRVE vs LLY·BRVE vs JNJ·BRVE vs ABBV·BRVE vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.